EGFR-targeted Therapy for Gastric Cancer | NCT04077255 | Trialant

EGFR-targeted Therapy for Gastric Cancer | NCT04077255 | Trialant

Sponsor/Collaborators Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
anti-EGFR	Experimental	Participants will receive GC-1118 in combination with weekly paclitaxel.	Drug: Anti-EGFR antibody in combination with weekly paclitaxel

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Anti-EGFR antibody in combination with weekly paclitaxel	Drug	Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
Progression-free survival	Time from date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed.	From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year.

Contacts/Locations Module